August 25, 2016

Sandoz’s authorized generic will be manufactured and supplied by Shire in 5-, 10-, 15-, 20-, 25- and 30-mg dosage strengths.

August 24, 2016
Apotex’s authorized generic will be available in 12.5-, 25- and 37.5-mg dosage strengths. 
August 23, 2016

The drug is indicated as a treatment for cleansing of the colon in preparation for colonoscopy in adults. 

August 22, 2016

A preliminary analysis in the study shows that payers might be able to save between $38 million and $63 million per 100,000 members by focusing on patients with three or more overlapping chronic conditions.

August 19, 2016

The product had U.S. sales of about $24.1 million for the 12 months ending June 2016, according to IMS Health.

August 18, 2016
Rob Monahan, most recently Walgreens’s VP mergers and acquisitions, has been named Akorn’s VP corporate development.  
August 18, 2016
he drug is indicated to treat certain types of brain cancer. 
August 18, 2016

Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. 

August 17, 2016

The review, published in the American Journal of Managed Care, looked at 26 studies of 27 formulary exclusions, 20 of which looked at the impact that exclusions had on patients. 

August 17, 2016
The death rate from opioid overdose in the United States had increased 200% since the year 2000, with deaths impacting people between ages 25 and 44 years, particularly in southern states. 
August 16, 2016
The Washington Examiner is reporting that Generic Pharmaceutical Association took an unconventional route to tout the savings that generics can bring to the U.S. healthcare system. As representatives from branded pharmaceuticals companies arrived at the Salt Lake City airport for Utah Sen. Orrin Hatch’s annual charity golf event, they saw billboards quoting a report from the Pharmaceutical Research and Manufacturers of America that said generics savings “free up resources to invest in new treatments…and resulting in significant progress against some of the most costly and challenging disease.” (Washington Examiner)
August 12, 2016

In addition to Idaho, CVS Pharmacy locations in 30 other states can dispense naloxone to patients without an individual prescription.

August 11, 2016

Lupin’s generic will be available in 600- and 800-mg dosage strengths.

August 10, 2016
The acquisition makes Mayne Pharma one of the 25 largest retail generic pharmaceutical companies in the United States and the second-largest generic oral contraceptive provider, the company said. 
August 5, 2016

Teva’s generic will be available in 100- and 400-mg dosage strengths.

August 4, 2016
The products have combined U.S. sales of $3.5 billion for the 12 months ended June 2016, according to IMS Health. 
August 4, 2016

USA Today is reporting that CVS Health has announced plans to remove two biologic drugs, Neupogen and Lantus, from its pharmacy benefits manager (PBM) formulary in 2017 and replace them with biosimilars of the drugs, substituting Zarxio for Neupogen and Basaglar for Lantus. Biosimilars cost about 15% to 30% less than the original biologics. CVS’s EVP and chief medical officer Troyen Brennan told USA Today that the biologics were reviewed by panels of experts “to make sure they are considered equivalent. (USA Today)

August 3, 2016

With generic drugs saving the healthcare system millions of dollars, Drug Store News caught up with Jim Cannon, Greenstone VP and general manager, to discuss authorized generics.

August 3, 2016

Drug Store News caught up with TopRx president Scott Franklin to discuss what’s on the horizon for the national distributor of generic pharmaceuticals.

August 3, 2016

Anda is the fourth-largest generics distributor in the U.S., and it distributes generic, branded and OTC pharmaceuticals from more than 300 manufacturers.

August 2, 2016

Total spending on products whose patents expired between 2012 and 2015 declined by $14.2 billion last year, according to IMS Health’s Institute for Health Care informatics. And 2016 could bring about further cost reductions.

August 2, 2016

As some companies prepare to market their biosimilars, others are still in development. At the end of 2015, the IMS Institute noted that there were five biosimilars in the pre-registration phase of development.

August 2, 2016

Due to an agreement with Ferring Pharmaceuticals, which markets Lysteda, Amerigen may launch its generic under license at an undisclosed future date. 

August 2, 2016
Mylan’s generic will be available in 5-, 10- and 15-mg dosage strengths.